V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Edgewise Therapeutics Executive Compensation (FY25)

EWTX · Executive and director compensation, fiscal 2023 to 2025

The Edgewise Therapeutics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 20, 2026Latest filing (8-K): June 5, 2026
2 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Edgewise Therapeutics brief$1,500Get the executive brief
174 figures on this page: 173 cited to the filing that reported them, 1 calculated from figures it prints. See the citations
Chief executive, fiscal 2025
◇
Kevin Koch
Median of the other named officers
$2,760,347
6 officers, excluding the chief executive
Latest say-on-pay support
=
June 4, 2026
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Kevin Koch: $7,601,200 → $7,359,546 (3.2% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Edgewise Therapeutics' chief executive and what were they paid?
Kevin Koch, President and Chief Executive Officer, received $7,359,546 in total compensation for fiscal 2025. Compared with the $7,601,200 reported for fiscal 2024, Koch's total was 3.2% lower.
What was Edgewise Therapeutics' say-on-pay result?
Shareholders supported the say-on-pay proposal with 96.1% of votes cast for or against in favor at the meeting held June 4, 2026 for fiscal 2025.
Which companies are in Edgewise Therapeutics' peer group?
The disclosed peer group names Aerovate Therapeutics, Akero Biosciences, Arcus Biosciences, Avidity Biosciences and Beam Therapeutics, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kevin Koch
President and Chief Executive Officer
◇——◇◇—◇◇
Behrad Derakhshan
Chief Operating Officer
◇——◇◇——◇
Joanne Donovan
Chief Medical Officer
◇——◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kevin Koch
President and Chief Executive Officer
◇—◇◇◇—◇◇
Joanne Donovan
Chief Medical Officer
◇———◇—◇— not reconciled
Behrad Derakhshan
Chief Operating Officer
◇———◇—◇— not reconciled
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kevin Koch
President and Chief Executive Officer
◇—◇◇◇—◇◇
Robert Blaustein
Former Chief Development Officer
Departed during or after this year
◇—◇◇◇—◇◇
Michael Nofi
Chief Financial Officer
◇—◇◇◇——◇
Behrad Derakhshan
Chief Operating Officer
◇—◇◇◇—◇◇
Joanne Donovan
Chief Medical Officer
◇———◇—◇— not reconciled
Alan Russell
Co-Founder and Chief Scientific Officer
◇———◇—◇— not reconciled
R. Michael Carruthers
Former Chief Financial Officer
Departed during or after this year
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Joanne DonovanRSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Behrad DerakhshanOption◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Kevin KochRSU◇◇——
RSU◇◇——
RSU◇———
RSU◇———
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Michael NofiRSU◇◇——
Option◇—◇—
Robert BlausteinRSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Alan RussellRSU◇◇——
RSU◇◇——
RSU◇———
RSU◇———
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
R. Michael CarruthersRSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Martin
◇—◇———◇
Peter Thompson, M.D
◇—◇———◇
Laura Brege
◇—◇———◇
Arlene M. Morris
◇—◇———◇
Jonathan Root, M.D
◇—◇———◇
Badreddin Edris, Ph.D
◇—◇———◇
Jonathan C. Fox, M.D., Ph.D
◇—◇———◇
Badreddin Edris
◇—————◇
Kevin Koch, Ph.D and Alan Russell, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Aerovate Therapeutics AVTE
  • Akero Biosciences symbol not shown
  • Arcus Biosciences RCUS
  • Avidity Biosciences RNA
  • Beam Therapeutics BEAM
  • Cogent Biosciences COGT
  • Denali Therapeutics DNLI
  • Dyne Therapeutics DYN
  • Enliven Therapeutics symbol not shown
  • IDEAYA Biosciences IDYA
  • Janux Therapeutics JANX
  • Keros Therapeutics KROS
  • Kymera Therapeutics KYMR
  • Pliant Therapeutics PLRX
  • Protagonist Therapeutics PTGX
  • Rocket Pharmaceuticals RCKT
  • Zentalis Pharmaceuticals ZNTL

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 4, 2026=◇◇◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Edgewise Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Edgewise Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Edgewise Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Edgewise Therapeutics' disclosed peer group is defensible, who names Edgewise Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
174 figures on this page: 173 cited to the filing that reported them, 1 calculated from figures it prints.
173 cited to the filing
1 calculated from the filing

Documents cited

  1. 0001104659-26-071011
    Item 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
  2. 0001104659-26-047688
    Director Compensation
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Edgewise Therapeutics executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/EWTX (accessed 2026).
Short form: data: Velarion

The Edgewise Therapeutics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
2 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Edgewise Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Edgewise Therapeutics discloses

The companies named in EWTX's own disclosed peer group.

Arcus BiosciencesAvidity BiosciencesBeam TherapeuticsCogent BiosciencesDenali TherapeuticsDyne TherapeuticsIDEAYA BiosciencesJanux TherapeuticsKeros TherapeuticsKymera TherapeuticsPliant TherapeuticsProtagonist TherapeuticsRocket PharmaceuticalsZentalis Pharmaceuticals

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy